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823-3 Effect of Intravenous Glycoprotein llblllla Receptor 
Antagonists on Survival in Percutaneous Coronary 
Interventions: A Meta-Analysis 
Evangelia Kawouni, Demosthenes G. Katritsia John P. loannidis, Athens Euroclinic, 
Athens, Greece, University of loannina School of Medicine, loannina, Greece 
Background. Several randomized trials have shown that intravenous antagonists of the 
platelet glycoprotein llblllla receptor reduce the incidence of myocardial infarction (Ml), 
and composite cardiac outcomes (death, MI or revascularization) in patients undergoing 
percu:utaneous coronary intervention (PCI). However, individual studies have not had ade- 
quate power to examine differences in mortality. 
Methods: We performed a meta-analysis of 19 randomized placebo-controlled trials (20 
comparisons, n=20,137) of intravenous glycoprotein llblllla receptor antagonists in 
patients undergoing PCI. Death was the primary outcome. 
Results:Mortality was significantly reduced at 30 days (risk ratio [RR] 0.69 [95% Cl, 
0.53-0.90]), 6 months (RR 0.79 [95% Cl, 0.64-0.97]), and including longer follow-up (RR 
0.79 [95% Cl, 0.66-0.941) with no significant between-study heterogeneity. The relative 
risk reduction was largely similar in trials on patients with or without acute MI; in trials 
continuing or discontinuing heparin after the procedure; and in trials using stents or other 
PCI as the intended primary procedure. At 30 days and 6 months, Ml and composite out- 
comes were significantly reduced pcO.001 for all). Major bleeding was significantly 
increased only in trials where heparin infusion was continued afler the procedure (RR 
1.70 [95% Cl, 1.36-2.141). while there was no excess bleeding when heparin was discon- 
tinued (RR 1.02 [95% Cl, 0.65.1.241). 
Conclusion:ln patients undergoing PCI, glycoprotein Ilb/llla receptor antagonists confer 
a significant, and sustained decrease in the risk of death. 
2:45 p.m. 
823-4 Prior Treatment With Statins Decreases Cardiac 
Biomarker Rise in Patients Undergoing Percutaneous 
Coronary Interventions 
Sean Halliqan, Joerg Hermann, Ryan Lennon, Geralyn Pumper, Stuart Higano, 
Verghese Mathew, David R. Holmes, Jr., Amir Lerman, Mayo Clinic-Rochester, 
Rochester, MN 
Background: Statins have been shown to reduce primary and secondary cardiac events 
in patients with coronary artery disease. However, it is unclear what the mechanism is for 
this benefit in patients undergoing precutaneous coronary intervention (PCI); we sought 
to determine if statins reduce the post-PC1 rise in cardiac biomarkers and postulated that 
this may be one mechanism for the observed benefit. 
Methods: We reviewed 1496 patents from the Mayo Clinic Interventional Registry who 
underwent PCI during the years 2000 and 2001. Patients with recent myocardial infarc- 
tion. shock, chronic renal disease or pre-procedural cardiac biomarker elevation were 
excluded. Patients were separated into two groups, Group 1 (n=752) consisted of 
patients on statins and Group 2 (n= 746) of patients not on statins prior to PCI. 
Results: Prior lo adjustment for baseline differences, Group 1 patients had a significantly 
lower rate of cardiac biomarker elevation post-PC1 compared to Group 2 patients (n= 200 
(27%) vs. n=236 (32%), p= 0.03). After adjusting for baseline differences, there were sig- 
nificantly fewer elevations in Troponin T levels (p=O.O49) and a trend towards fewer ele- 
vations of any cardiac enzymes (p=O.O56) post-procedure in Group 1. At follow up, 
unadjusted Kaplan-Meier curves indicate a significantly lower rate of death or myocardial 
infarction in Group 1 patients (p=O.O12). 
Conclusions: In this retrospective study, patients on statin therapy prior to PCI had a 
lower rise in cardiac biomarkers than those not on statin therapy. This maybe a mecha- 
nism for the cardiovascular benefits seen in patients on statins undergoing PCI. 
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823-5 Clopidogrel Pretreatment Reduces Platelet 
Inflammatory Marker Expression in Patients 
Undergoing Percutaneous Coronary Intervention 
Frank J. Zidar, Martin J. Quinn, Deepak L. Bhatt, Deepak P. Vivekananthan, Herbert D. 
Aronow. Stephen G. Ellis, Edward Plow, Eric J. Top& The Cleveland Clinic Foundation. 
Cleveland, OH 
Background: Inflammation is thought to play an important role in the pathogenesis of 
complications after percutaneous coronary intervention (PCI). Pretreatment with the 
platelet ADP receptor antagonist clopidogrel reduces ischemic complications after PCI. 
We examined the effect of clopidogrel pretreatment (>24 hours) on platelet inflammatory 
marker expression after PCI. 
Methods: Patients undergoing elective PCI at the Cleveland Clinic were recruited into 
the study. Platelet and serum expression of the inflammatory markers CD40L and 
CD62P were compared in patients pretreated or not pretreated with clopidogrel. Blood 
was drawn before and after PCI. Platelet CD40L and CD62P expression in ADP (30pM) 
and TRAP (%M) activated samples were quantified by flow cytometry. Results are pre- 
sented as the geometric mean fluorescence intensity of the platelet population minus the 
fluoresence of isolypic control antibody. Soluble .CD40L levels were determined by 
ELISA. 
Results: Complete data was available on 71 patients. 30 (42%) were pretreated with clo- 
pidogrel for a median of 5 days. Mean age was 66+11 years, 75% were male. 
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Preprocedure no pre-rx clap. pre 
CD40L (ADP) 2.72 1.74 
CD40L (TRAP) 5.18 4.06 
CD62P (ADP) 196.01 75.71 
CD62P (TRAP) 274.51 166.00 
soluble CD40L 1.21 1.06 
Postprocedure 
CD40L (ADP) 2.75 1.26 
CD40L (TRAP) 4.50 1.79 
CD62P (ADP) 141.17 57.71 
CD62P (TRAP) 208.64 135.17 
soluble CD40L 0.17 0.10 
-rx p value 
p = .I1 
p = .42 
p = .0003 
p = ,024 
p = .85 
p = .I4 
p = ,019 
p=.OcO2 
p=.O55 
p = ,028 
Conclusions: Clopidogrel pretreatment reduces platelet inflammatory marker expres- 
sion, specifically CD62P. prior to and immediately after PCI. Pretreatment may also 
decrease levels of soluble CD40 after PCI. In addition to the known anti-platelet activity 
of clopidogrel, these anti-inflammatory eflects may explain part of the clinical benefit of a 
clopidogrel pretreatment strategy. 
3:15 p.m. 
823-6 Benefit of Clopidogrel in Patients Undergoing 
Percutaneous Coronary Intervention in the CURE Trial 
Receiving and Not Receiving an lntracoronary Stent 
Shamir R. Mehta, Madhu K. Natarajan, Thomas Wittlinger, Joao Morais. Matyas Keltai, 
Hans-Jurgen Rupprecht, Michel E. Bertrand, Keith A. Fox, Salim Yusuf. McMaster 
University, Hamilton, ON, Canada 
Background: It is well established that patients undergoing percutaneous coronary 
intervention (PCI) receiving a stent benefit from treatment with clopidogrel, in addition lo 
aspirin. In certain situations. it may not be possible to insert a stent. This analysis 
explores the consistency of benefit with clopidogrel in those patients treated with and 
without a stent. 
Methods: In the CURE trial, patients were randomized to receive clopidogrel 300 mg 
loading dose. followed by 75 mg a day for up to one year or matching placebo, in addition 
to aspwn. The 2,552 patients undergoing PCI in the trial were divided into 2 groups: 
those receiving a stent and those not receiving a stent. Outcome events, cardiovascular 
(CV) death or myocardial infarction (Ml), were analyzed in these groups lo determine if 
there was consistency of benefit with clopidogrel. 
Results: Overall, among the 2,552 patients undergoing PCI in the CURE study, there 
was a significant reduction In CV death or Ml with clopidogrel compared with placebo 
(relative risk reduction 31%, P=O.O02). 466 patients did not receive an intracoronary stem 
(253 placebo and 233 clopidogrel) and 2066 received at least one stem (1092 placebo 
and 1060 clopidogrel). Clopidogrel was beneficial both in those not receiving a stent 
(RRR 44%. P=O.O26) and in those receiving a stent (RRR 27%, P=O.O20) (Table). 
Conclusion: In patients with ACS undergoing PCI, clopidogrel is beneficial in those 
treated with a stem. and in those receiving balloon angioplasty alone. 
CV death or Ml from random,zanon to end (up ,o 1 year) 
Group Placebo Clopidogrel Relative Risk 95% Cl P value 
All patients 169/1345 (12.6%) 116/1313 (6.6%) 0.69 0.54-0.67 0.002 
No Stent 41/253 (16.2%) 221233 (9.4%) 0.56 0.34-0.95 0.026 
stent 126/1092 (11.7%) 94/1060 (6.7%) 0.73 0.56-0.95 0.020 
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1127-187 The French Registry of Left Main Coronary Artery 
Treatment: Preliminary Results 
Marc Silvestri, Thieny Lefkre, Pierre Labrunie, Khalife Khalife, G. Bayet. Marie-Claude 
Morice M. Bedossa. A. Chmait, On behalf of the FLM Registry Investigators. UCV, -1 
Marseille, France, lnstitut Cardiovasculaire Paris Sud, Massy, France 
Background: CABG is the established treatment for unprotected left main coronary 
artery lesions (LMCA). However, PCI is now proposed as an alternative 
Methods:A prospective registry was set-up in 11 high-volume French centers during 13 
months to evaluate the outcome of pts with LMCA. 
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Results : From May 01 to June 02, 483 Pts were included, age 6&l 1 y, unstable angina 
41%, 3 vessel disease 42%, distal LMCA 56%, EF 56216%. They were classified as 
good candidates for surgery in 62%, poor in 33% and contra-indicated in 5%. Treatment 
was CABG in 46%, PCI in 40% and medical in 12%. Main characteristics were similar in 
the CABG and PCI groups except for an excess of poor candidates in the PCI group 
compared to surgery (45 vs 14%, p ~0.001) and more RCA lesions in the CABG group 
(67 vs 43%, p<O.OOl). In the PCI group, Gp2b3a inhibitors were used in 21% and intra- 
aortic balloon pump in 9%. All Pts were stented on the LMCA (1.1+0.4 stents, diameter 
3.QO.3 mm, length 11.6+3.5 mm). Before stenting, rotational atherectomy was used in 
7%, cutting balloon in 4% and balloon predilatation in 55% of cases. Angiographic suc- 
cess was obtained in all cases. LMCA MLD increased from 1.+0.7 to 3.7?;0.6mm. Stay 
was 15221 days in the CABG group vs 5+3 in the PCI group (pcO.001). Mortality rate 
was as follows (preliminary): 
Conclusion: Despite unfavorable characteristics, PCI for LMCA is associated with 
excellent l-month and promising mid-term outcome compared to CABG. Complete 6- 
month follow-up will be presented at the meeting. 
1 month 6 month 12 month 
PCI (n=l631102/31) 0.5% 3.6% 4.1% 
CABG (n=l42/83/70) 5.5%. 6.4% 7.2% 
Medical (n=46/30/30) 14.0%’ 22.0%’ 22.0% 
* p<o.o5 
1127-188 Can Tapered-Tip Guidewires Improve the Success Rate 
of Percutaneous Coronary Intervention in Chronic Total 
Occlusion? 
Shiaefu Saito, Shinji Tanaka, Saeko Takahashi, Yusuke Miyashita, Yoshltaka Hiroe, 
Shutaro Satake, SanQing Jia, Shonan Kamakura General Hospital, Kamakura, Japan, 
Beijing Friendship Hospital, Beitmg, People’s Republic of China 
Backgrounds: Percutaneous coronary Intervention (PCI) for chronic total occlusion 
(CTO) is still technically challenging. The use of tapered-tip guidewires (Cross-itR or Con- 
questR), which were specifically designed for CT0 lesions, may improve the success rate 
of PCI in these lesions. 
Objectives and Methods: In order to know whether the introduction of tapered-tip 
guidewires could improve the success rate, we retrospectively compared the results of 
PGI in CT0 lesions in 162 patients during Phase I period (between April 1997 and 
December 1999) with those in 80 patients during Phase II period (between January and 
August 2001). 
Results: 
Phase I Phase11 P 
No. of patients 182 60 
Male gender 76% 63% NS 
Age 65 +I- 11 67 +/- 6 NS 
Triple vessel disease 21% 20% NS 
LVEF 49 +/- 18% 49 +/- 13% NS 
Duration of occlusion (months) 15 +/- IO 17+/-26 NS 
Length of occlusion (mm) 17+/-5 16+/-6 NS 
Tapered-type occlusion 33% 35% NS 
Contra-lateral angiography 20% 23% NS 
Use of hydrophilic guidewires 6% 6% NS 
Use of tapered-tip guidewires 0 60% <0.001 
The overall success rate was improved from 67% in Phase I to 61% in Phase II 
(p=0.019). 
Conclusions: The use of tapered-ttp guldewires can improve the success rate of PCI in 
CT0 lesions. 
1127-189 Adjunctive Porous Filter Protection From Distal 
Emboliration in Primary Percutaneous Intervention for 
Acute Myocardial Infarction 
Uqo Limbrunq Andrea Micheli, Anna S. Petronio, Caterina Palagi, Giovanni Amoroso, 
Marco De Carlo, Roberta Rossini, Daniele Carbocci, Paolo Caravelli, Vitoantonio Di 
Belle, Mario Mariani. University of Pisa, Pisa, Italy 
Background: Effective reperfusion after primary percutaneous coronary intervention 
(PCI) in patients with acute myocardial infarction may be affected by distal embolization. 
We tested safety and feasibility of the adjunctive use of “Filter-wire Ex’ (FW), a non- 
occluding porous filter device aimed to prevent distal embolism, during primary PCI on 
native coronary vessels. 
Methods: Twenty-eight consecutive patients admitted < 6 hours after acute myocardial 
infarction onset were treated by primary PCI in association with FW to prevent distal 
embolism. Clinical outcome of these patients (group FW) was compared to 26 patients 
with acute myocardial infarction treated by primary PCI alone (group PCI) matched for 
age, sex and infarct location. Patients with cardiogenic shock, left main coronary artery 
disease, pre-PCI TIMI grade flow >I in the Infarct vessel or infarct vessel size < 3.0 mm 
were excluded from the study. 
Results: Successful positioning of FW device was obtalned in 26 out of 28 patients. All 
positioned FW were safely retrieved. Visible emboli in the FW basket were recovered in 6 
patients (thrombus in 6 patients, plaque debris in 2 patients). Coronary dissections due to 
FW device positioning or retrieval were not ovserved. Use of FW was moderately time 
consuming (arterial puncture-to-vessel recanalization time in FW and PCI groups: 24*5 
YS 20*5 min, p<O.O5). A final Thrombolysis ln Myocardial lnfarctlon (TIMI) flow grade < 3 
and persistent ST-segment elevation at the end of PCI were less frequent in the FW with 
respect to the PCI group (final TIMI flow grade: 4% vs 21%. p: N.S.; persistent ST-seg- 
ment elevetion: 7% vs 36%. pcO.05). Moreover, patients in the FW group showed signifi- 
cantly lower peak creatin kinase-MB release (212+181 U/I vs 34&216 U/I, pqO.02) as 
well as greater improvement in left ventricular PD-echo regional wall motion index at 4 
weeks (-0.40*0.25 vs -0.21+0.26, ~0.01). 
Conclusion: This is the first clinical study showing that the adjunctive use of the distal 
embolism protectIon device FW during primary PCI is safe and technlcally feasible, even 
I” native coronary arteries. In this clinical setting, FW seems able to improve eflectlve 
reperfusion. 
1127-190 Gender-Based Differences in Long-Term Outcome 
Following Percutaneous Coronary Intervention 
Jeffrev S. Beraer, Babak A. Vakili. Timothy A. Sanborn. Warren Sherman, Kumar L. 
Ravi, David L. Brown, Beth Israel Medical Center, New York, NY 
Background: Early studies suggested that morbidity and mortality following percutane- 
ous coronary intervention (PCI) were greater in women than men. However, in recent 
reports, gender-related differences in short-term outcome have decreased as outcomes 
among women have improved. We sought to evaluate the effect of gender on long-term 
mortality among a large cohort of patients undergoing PCI I” the contemporary era. 
Methods: Three hospitals in New York City contributed prospectively defined data ele- 
ments on 4264 consecutive patients undergoing PCI in 1996-9. All-cause mortality at a 
mean follow-up of 3 years was the primary endpoint. Results: Of the 4264 patients, 
1,331 (31%) were female. Females were significantly older than males (mean age 67 vs. 
62 years, P<O.OOl) and less often white (72% vs.EO%, P<O.OOl). Hypertension (76% vs. 
66%. P<O.OOl) and diabetes (36% vs. 22%, PcO.001) were more prevalent in females. 
Prior cardiac surgery (14% vs. 19% P=O.OOl) and previous myocardial infarction (Ml) 
(33% vs. 36%, P=O.O6) were less common among women. Presentation with unstable 
angina was more frequent in women (45% vs. 41%, P=O.O34) whereas presentation with 
acute MI did not differ by gender. Congestive heart failure developed more commonly 
among women (7.1% vs. 4.1 %, P<O.OOl). The extent of coronary disease (one-, two- or 
three-vessel disease) did not differ between females and males. Mean etectlon fraction 
was 52% in women and 50% in men (PcO.001). Stents were placed in 77% of both 
groups. Angiographic success was 97% for both women and men. In-hospital adverse 
outcomes including death, post-PC1 MI, emergency bypass surgery. abrupt closure and 
stent thrombosis were uncommon and not different between groups. Mortality at 3 years 
was 10% for men and 8.9% for women (P=O.l97). However, using Cox proportional haz- 
ards analysis to adjust for co-morbidities and possible confounders, female gender was 
associated with a significant independent reduction in the hazard of long-term mortality 
(Hazard Ratio, 0.775, 95% Confidence Interval, 0.620-0.969, P=O.O25). Conclusion: 
Despite more high-risk charcteristics, female gender confers a long-term survival advan- 
tage following PCI. 
1127-191 Predictors of New Renal Dialysis After Percutaneous 
Coronary Intervention 
Beth A. Bartholomew, Srinivas Dukklpati, Kishore J. Harjai, Judith A. Boura, Datinder 
Deo, Michael W. Yerkey, H. Mehrdad Sadeghi, William W. CSNeill, Joel K. Kahn. William 
Beaumont Hospital, Royal Oak, Ml 
Background: Acute renal failure requiring hemodialysis (HD) is an infrequent but serious 
complication of percutaneous coronary intervention (PCI). The risk factors for HD have 
not been well elucidated in a large population. 
Methods: We reviewed 31,397 PCI procedures in the William Beaumont Hospital PCI 
database from May 1993 to May 2002. Patients undergoing CABG surgery were 
excluded (11~336). We assessed the incidence and independent predictors of acute renal 
failure requiring HD. 
Results: The incidence of HD was 0.3%. Characteristics predicting renal failure requiring 
HD are shown in the table. Interestingly, contrast volume over 15Occ was not predictive 
of HD. 
Conclusions: Renal failure requiring HD is infrequent with an incidence of 0.3%. Preexist- 
Ing renal dysfunction remains the strongest predictor of new hemodialysis. 
Predictors of Hemadialysis 
P value Odds Ratio 95% Cl 
Creatinine Clearance <75mllmin <0.0009 29.1 4.00-212 
Unplanned IA6 P <0.0001 5.54 3.01-10.2 
CHF <0.0001 5.31 2.93-9.63 
urgent PCI 0.0009 4.90 1.92-l 2.5 
Diabetes <0.0001 4.75 2.56-8.76 
Peripheral Vascular Disease 0.026 1.93 1.08-3.44 
